Results Reinforce Merck/Kelun’s Sac-TMT As Major TROP2 Player

Edwards LifesciencesEdwards Lifesciences stock (US28176E1082): heart-valve specialist in focus after latest earnings upd - AD HOC NEWS

Charles RiverCharles River Laboratories stock (US1591881009): Fresh earnings and outlook keep investors focused o - AD HOC NEWS

Lonza NewsLonza Group AG stock (CH0013841017): pharma supplier in focus after 2025 results and dividend decisi - AD HOC NEWS

LabCorpLabcorp stock (US50540R4092): Q1 results, new contracts and healthcare demand in focus - AD HOC NEWS

QiagenQiagen N.V. stock (NL0012169213): diagnostics specialist updates investors after Q1 results - AD HOC NEWS

WuXi AppTecWuXi AppTec Supports a More Connected Life Sciences Ecosystem Through Collaboration - Issuewire

AmgenBiopharma bites: IRA is here to stay, plus more safety concerns for Amgen's Tavneos - FirstWord Pharma

10x Genomics NewsThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com

Mettler ToledoMettler-Toledo stock (US5926881054): Q1 results and guidance reset grab Wall Street's attention - AD HOC NEWS

QiagenQiagen stock (NL0012169213): New strategic tie-up puts diagnostics in focus - AD HOC NEWS

FierceBiotechSanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought

NovartisNovartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims - Fierce Pharma